BALAXI PHARMACEUTICALS LIMITED
Balaxi Pharmaceuticals Limited engages in the international wholesale distribution of pharmaceuticals, builders hardware, and FMCG products in Africa, the Caribbean Islands, and Latin America. The company offers pharmaceutical products across various therapeutic areas that mainly treats antibiotics, analgesic, anti-malaria, and others. It also provides biscuits and toothpastes. The company was fo… Read more
BALAXI PHARMACEUTICALS LIMITED (BALAXI) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.063x
Based on the latest financial reports, BALAXI PHARMACEUTICALS LIMITED (BALAXI) has a cash flow conversion efficiency ratio of 0.063x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₹149.66 Million) by net assets (₹2.38 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
BALAXI PHARMACEUTICALS LIMITED - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how BALAXI PHARMACEUTICALS LIMITED's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
BALAXI PHARMACEUTICALS LIMITED Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BALAXI PHARMACEUTICALS LIMITED ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
DistIT AB (publ)
ST:DIST
|
-0.223x |
|
C2C Gold Corp
OTCQB:CTCGF
|
-0.008x |
|
Abéo SA
LSE:0RJY
|
N/A |
|
Alien Metals Ltd
PINK:ASLRF
|
-0.035x |
|
IMAGIS Co. Ltd
KQ:115610
|
-0.007x |
|
Cubtek Inc.
TWO:2252
|
-0.226x |
|
Western Bulk Chartering AS
PINK:WSSTF
|
0.042x |
|
Hemostemix Inc
OTCQB:HMTXF
|
0.839x |
Annual Cash Flow Conversion Efficiency for BALAXI PHARMACEUTICALS LIMITED (2013–2025)
The table below shows the annual cash flow conversion efficiency of BALAXI PHARMACEUTICALS LIMITED from 2013 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | ₹2.32 Billion | ₹-377.82 Million | -0.163x | -774.66% |
| 2024-03-31 | ₹2.01 Billion | ₹48.66 Million | 0.024x | -27.26% |
| 2023-03-31 | ₹1.83 Billion | ₹60.75 Million | 0.033x | -88.99% |
| 2022-03-31 | ₹1.13 Billion | ₹341.44 Million | 0.302x | +632353.73% |
| 2021-03-31 | ₹649.80 Million | ₹31.00K | 0.000x | +100.01% |
| 2020-03-31 | ₹277.46 Million | ₹-140.62 Million | -0.507x | -18.39% |
| 2019-03-31 | ₹35.21 Million | ₹-15.07 Million | -0.428x | +1.89% |
| 2018-03-31 | ₹15.55 Million | ₹-6.78 Million | -0.436x | -3.84% |
| 2017-03-31 | ₹23.59 Million | ₹-9.91 Million | -0.420x | +88.57% |
| 2016-03-31 | ₹314.87K | ₹-1.16 Million | -3.676x | -156.12% |
| 2015-03-31 | ₹322.45K | ₹2.11 Million | 6.551x | +2233.63% |
| 2014-03-31 | ₹7.80 Million | ₹-2.39 Million | -0.307x | -171.16% |
| 2013-03-31 | ₹7.52 Million | ₹3.25 Million | 0.431x | -- |